Skyhawk Therapeutics, Inc.

Ipsen SA appears to have reset the market for US Food and Drug Administration priority review vouchers after selling its voucher to an unnamed company for $158m. Ipsen received the voucher, which can

Ipsen SA has shown itself to be a canny dealmaker over the past few years and its negotiating skills have been shown again with the sale of a priority review voucher (PRV) at well above market rate.

Ipsen SA is showing no sign of slowing down on the dealmaking front and has bagged the ex-US licensing rights to Day One Biopharmaceuticals, LLC 's recently approved brain cancer drug, Ojemda. The F

The Upside Of Scarcity: Canaan’s Kjellson On The Virtues Of Lean Thinking While biotech startups may be struggling to raise funds in today’s financial environment, Nina Kjellson, general partner/West